Status:
UNKNOWN
HCV Reinfection in HD Patients Achieving SVR
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Hepatitis C Virus Infection
Hepatitis C Virus Infection, Response to Therapy of
Eligibility:
All Genders
20+ years
Brief Summary
Among the hemodialysis units, the global incidence of HCV infection ranges from 1.2% to 2.9%. Data regarding the long-term risk of reinfection among hemodialysis patients achieving SVR are limited. To...
Detailed Description
Hepatitis C virus (HCV) infection is an important public health problem. Compared to the global prevalence of HCV infection to be around 1.0%, the prevalence of HCV infection in hemodialysis patients ...
Eligibility Criteria
Inclusion
- Age old than 20 years old
- Patients receiving hemodialysis during interferon (IFN)-based or IFN-free antiviral therapy
- Patients achieving sustained virologic response (SVR), defined as undetectable serum HCV RNA at week 12 off-therapy
Exclusion
- Poor access to sites for venipuncture
Key Trial Info
Start Date :
February 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2024
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT04732832
Start Date
February 1 2021
End Date
March 1 2024
Last Update
February 24 2021
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital, Yun-Lin Branch
Douliu, Taiwan, 640
2
China Medical University Hospital
Taichung, Taiwan, 40447
3
Taichung Veterans General Hospital
Taichung, Taiwan, 40705
4
National Taiwan University Hospital
Taipei, Taiwan, 100